New CAR T-cell therapy targeting cancer-associated antigens
Official title: CD28-KITv CAR T cells with PD-1 dominant negative receptor
Funded at Sloan-Kettering Inst Can Research · NIH-11043413 · Data updated 2026-11-12
This study is testing a new type of CAR T-cell therapy that helps your immune cells better fight cancer by targeting a protein called mesothelin, and it's specifically for patients with malignant pleural mesothelioma to see if it can improve treatment results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,570,342 |
| NIH project number | 5UG3CA290241-02 |
| Project ID | NIH-11043413 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with solid tumors, particularly those expressing mesothelin, and who have not responded to conventional therapies.
✕Less likely to help
Patients with tumors that do not express mesothelin or those who are not eligible for CAR T-cell therapy may not benefit from this research.
What this research studies
This research investigates a novel approach to CAR T-cell therapy that targets mesothelin, a protein found in many solid tumors. The therapy aims to enhance the effectiveness of T-cells in fighting cancer by using a specific mutation to improve their ability to infiltrate tumors and avoid toxicity to healthy tissues. Patients will receive CAR T-cells that are designed to overcome challenges such as T-cell exhaustion and immunosuppressive environments, potentially leading to better treatment outcomes. The study includes administering these modified T-cells directly into the pleural space for patients with malignant pleural mesothelioma.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with solid tumors, improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with CAR T-cell therapies targeting specific antigens in solid tumors, indicating potential for success with this novel approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Adusumilli, Prasad S. — Sloan-Kettering Inst Can Research
- Study coordinator: Adusumilli, Prasad S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.